Cutaneous adverse effects of the immune checkpoint inhibitors

The immune checkpoint targeted agents, anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and anti-programed cell death-1 (PD-1)/anti-programmed death-ligand 1 (PD-L1) inhibitors are frequently associated with cutaneous side effects, which are often dose-limiting and can lead to discontinuation of therapy. Ipilimumab, a CTLA-4 inhibitor, is most commonly associated with a morbilliform eruption on the trunk and extremities and pruritus. More severe cutaneous toxicities reported include toxic epidermal necrolysis (TEN) and severe drug rash with eosinophila and systemic symptoms (DRESS).

Source: Current Problems in Cancer - December 13, 2016 Category: Cancer & Oncology Authors: Lindsey K. Collins, M. Shane Chapman, Joi B. Carter, Faramarz H. Samie Source Type: research